These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8699067)

  • 1. Safety, immunogenicity, and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes.
    Heppner DG; Gordon DM; Gross M; Wellde B; Leitner W; Krzych U; Schneider I; Wirtz RA; Richards RL; Trofa A; Hall T; Sadoff JC; Boerger P; Alving CR; Sylvester DR; Porter TG; Ballou WR
    J Infect Dis; 1996 Aug; 174(2):361-6. PubMed ID: 8699067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine.
    Gordon DM; McGovern TW; Krzych U; Cohen JC; Schneider I; LaChance R; Heppner DG; Yuan G; Hollingdale M; Slaoui M
    J Infect Dis; 1995 Jun; 171(6):1576-85. PubMed ID: 7769295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group.
    Stoute JA; Slaoui M; Heppner DG; Momin P; Kester KE; Desmons P; Wellde BT; Garçon N; Krzych U; Marchand M
    N Engl J Med; 1997 Jan; 336(2):86-91. PubMed ID: 8988885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013.
    Genito CJ; Beck Z; Phares TW; Kalle F; Limbach KJ; Stefaniak ME; Patterson NB; Bergmann-Leitner ES; Waters NC; Matyas GR; Alving CR; Dutta S
    Vaccine; 2017 Jul; 35(31):3865-3874. PubMed ID: 28596090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, immunogenicity, and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell wall skeleton of mycobacteria, and squalane as adjuvant.
    Hoffman SL; Edelman R; Bryan JP; Schneider I; Davis J; Sedegah M; Gordon D; Church P; Gross M; Silverman C
    Am J Trop Med Hyg; 1994 Nov; 51(5):603-12. PubMed ID: 7985753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175.
    Chitnis CE; Mukherjee P; Mehta S; Yazdani SS; Dhawan S; Shakri AR; Bhardwaj R; Gupta PK; Hans D; Mazumdar S; Singh B; Kumar S; Pandey G; Parulekar V; Imbault N; Shivyogi P; Godbole G; Mohan K; Leroy O; Singh K; Chauhan VS
    PLoS One; 2015; 10(4):e0117820. PubMed ID: 25927360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of a recombinant nonglycosylated erythrocyte binding antigen 175 Region II malaria vaccine in healthy adults living in an area where malaria is not endemic.
    El Sahly HM; Patel SM; Atmar RL; Lanford TA; Dube T; Thompson D; Sim BK; Long C; Keitel WA
    Clin Vaccine Immunol; 2010 Oct; 17(10):1552-9. PubMed ID: 20702657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component.
    Tamminga C; Sedegah M; Regis D; Chuang I; Epstein JE; Spring M; Mendoza-Silveiras J; McGrath S; Maiolatesi S; Reyes S; Steinbeiss V; Fedders C; Smith K; House B; Ganeshan H; Lejano J; Abot E; Banania GJ; Sayo R; Farooq F; Belmonte M; Murphy J; Komisar J; Williams J; Shi M; Brambilla D; Manohar N; Richie NO; Wood C; Limbach K; Patterson NB; Bruder JT; Doolan DL; King CR; Diggs C; Soisson L; Carucci D; Levine G; Dutta S; Hollingdale MR; Ockenhouse CF; Richie TL
    PLoS One; 2011; 6(10):e25868. PubMed ID: 22003411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes.
    Nardin EH; Oliveira GA; Calvo-Calle JM; Wetzel K; Maier C; Birkett AJ; Sarpotdar P; Corado ML; Thornton GB; Schmidt A
    Infect Immun; 2004 Nov; 72(11):6519-27. PubMed ID: 15501783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, immunogenicity, and pilot efficacy of Plasmodium falciparum sporozoite and asexual blood-stage combination vaccine in Swiss adults.
    Sturchler D; Berger R; Rudin C; Just M; Saul A; Rzepczyk C; Brown G; Anders R; Coppel R; Woodrow G
    Am J Trop Med Hyg; 1995 Oct; 53(4):423-31. PubMed ID: 7485698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant Full-length Plasmodium falciparum Circumsporozoite Protein-Based Vaccine Adjuvanted With Glucopyranosyl Lipid A-Liposome Quillaja saponaria 21: Results of Phase 1 Testing With Malaria Challenge.
    Friedman-Klabanoff DJ; Berry AA; Travassos MA; Shriver M; Cox C; Butts J; Lundeen JS; Strauss KA; Joshi S; Shrestha B; Mo AX; Nomicos EYH; Deye GA; Regules JA; Bergmann-Leitner ES; Pasetti MF; Laurens MB
    J Infect Dis; 2024 Jun; 229(6):1883-1893. PubMed ID: 38330357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice.
    Schwenk R; DeBot M; Porter M; Nikki J; Rein L; Spaccapelo R; Crisanti A; Wightman PD; Ockenhouse CF; Dutta S
    PLoS One; 2014; 9(10):e111020. PubMed ID: 25343487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia.
    Doherty JF; Pinder M; Tornieporth N; Carton C; Vigneron L; Milligan P; Ballou WR; Holland CA; Kester KE; Voss G; Momin P; Greenwood BM; McAdam KP; Cohen J
    Am J Trop Med Hyg; 1999 Dec; 61(6):865-8. PubMed ID: 10674660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A monoclonal antibody-based immunoassay to measure the antibody response against the repeat region of the circumsporozoite protein of Plasmodium falciparum.
    Radin K; Clement F; Jongert E; Sterckx YG; Ockenhouse C; Regules J; Lemiale F; Leroux-Roels G
    Malar J; 2016 Nov; 15(1):543. PubMed ID: 27825382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irradiated sporozoite vaccine induces HLA-B8-restricted cytotoxic T lymphocyte responses against two overlapping epitopes of the Plasmodium falciparum sporozoite surface protein 2.
    Wizel B; Houghten RA; Parker KC; Coligan JE; Church P; Gordon DM; Ballou WR; Hoffman SL
    J Exp Med; 1995 Nov; 182(5):1435-45. PubMed ID: 7595214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection.
    Cummings JF; Spring MD; Schwenk RJ; Ockenhouse CF; Kester KE; Polhemus ME; Walsh DS; Yoon IK; Prosperi C; Juompan LY; Lanar DE; Krzych U; Hall BT; Ware LA; Stewart VA; Williams J; Dowler M; Nielsen RK; Hillier CJ; Giersing BK; Dubovsky F; Malkin E; Tucker K; Dubois MC; Cohen JD; Ballou WR; Heppner DG
    Vaccine; 2010 Jul; 28(31):5135-44. PubMed ID: 19737527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of cytolytic and antibody responses using Plasmodium falciparum repeatless circumsporozoite protein encapsulated in liposomes.
    White K; Krzych U; Gordon DM; Porter TG; Richards RL; Alving CR; Deal CD; Hollingdale M; Silverman C; Sylvester DR
    Vaccine; 1993 Oct; 11(13):1341-6. PubMed ID: 7507624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, toxicity and immunogenicity of a malaria vaccine based on the circumsporozoite protein (FMP013) with the adjuvant army liposome formulation containing QS21 (ALFQ).
    Cawlfield A; Genito CJ; Beck Z; Bergmann-Leitner ES; Bitzer AA; Soto K; Zou X; Hadiwidjojo SH; Gerbasi RV; Mullins AB; Noe A; Waters NC; Alving CR; Matyas GR; Dutta S
    Vaccine; 2019 Jun; 37(29):3793-3803. PubMed ID: 31151801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria.
    Malkin E; Hu J; Li Z; Chen Z; Bi X; Reed Z; Dubovsky F; Liu J; Wang Q; Pan X; Chen T; Giersing B; Xu Y; Kang X; Gu J; Shen Q; Tucker K; Tierney E; Pan W; Long C; Cao Z
    Vaccine; 2008 Dec; 26(52):6864-73. PubMed ID: 18930094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21.
    Kashala O; Amador R; Valero MV; Moreno A; Barbosa A; Nickel B; Daubenberger CA; Guzman F; Pluschke G; Patarroyo ME
    Vaccine; 2002 May; 20(17-18):2263-77. PubMed ID: 12009282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.